Surprisingly, the NBL cohort in fact had significantly higher levels of CD8+ TILs than both groups of adult tumors (Figure 2); the median absolute fraction of CD8+ TILs was more than three times higher than in the cohort of adult cancers with ICI approved by FDA, and more than four times higher than the median absolute fraction in the non‐ICI approved group. This evidence concerns the gene CD8A and cancer.